New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
05:26 EDTCRLCharles River Labs sees acquisition of CRO services accretive to FY14 EPS by 10c
Charles River Laboratories International announced that it has completed the previously announced acquisition of the CRO services division of Galapagos NV, which includes both Argenta and BioFocus. The acquisition positions Charles River as a full service, early-stage contract research organization, or CRO, with integrated in vitro and in vivo capabilities from target discovery through preclinical development. The acquisition is expected to add approximately 6% to Charles Riverís net sales in 2014. It is also expected to be accretive to non-GAAP EPS in 2014 by approximately 10c. Items excluded from non-GAAP earnings per share are expected to include all deal-related costs including amortization of intangible assets.
News For CRL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2015
16:19 EDTCRLCharles River acquires Oncotest GmbH for EUR34M
Charles River has acquired Oncotest GmbH, a Freiburg, Germany-based contract research organization providing discovery services for oncology. Oncotest offers an integrated portfolio of target discovery and validation services for preclinical oncology researchers, specializing in in vivo pharmacology services. The purchase price was approximately EUR34M in cash, approximately $36M at current exchange rates. The transaction includes a potential additional payment of EUR2M based on future performance. The purchase price implies a multiple of approximately 11x adjusted EBITDA based on the trailing twelve months ended September 2015. The acquisition will have a negligible impact on Charles River's consolidated revenue and non-GAAP EPS in Q4. In 2016, Oncotest is expected to represent approximately 1% of Charles River's consolidated revenue and be neutral to slightly accretive to non-GAAP EPS.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use